about
Lipoprotein(a) as a cardiovascular risk factor: current statusThe 1st and the 2nd Italian Consensus Conferences on low-density lipoprotein-apheresis. A practical synopsis and updateChallenges in the Diagnosis and Treatment of Homozygous Familial HypercholesterolemiaOptimizing Treatment of Familial Hypercholesterolemia in Children and AdolescentsFamilial hypercholesterolemia: present and future managementThe panorama of familial hypercholesterolemia in Latin America: a systematic review.Guideline on the clinical use of apheresis procedures for the treatment of patients and collection of cellular therapy products. British Committee for Standards in Haematology.Lipoprotein (a), an independent cardiovascular risk markerFamilial hypercholesterolemia: A reviewLipid-apheresis improves microcirculation of the upper limbs.Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis.Drug therapy of hypercholesterolaemia in children and adolescents.Use of ultra high performance liquid chromatography-tandem mass spectrometry to demonstrate decreased serum statin levels after extracorporeal LDL-cholesterol elimination.LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectivesRandomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy.Dementia Improvement after Plasma Exchange for Familial Hypercholesterolemia.The genetics of familial hypercholesterolemia and emerging therapiesChanges in Lipids and Lipoproteins after Selective LDL Apheresis (7-Year Experience)LDL-apheresis depletes apoE-HDL and pre-β1-HDL in familial hypercholesterolemia: relevance to atheroprotection.A model of care for familial hypercholesterolaemia: key role for clinical biochemistry.Impact of LDL apheresis on atheroprotective reverse cholesterol transport pathway in familial hypercholesterolemiaHELP apheresis in hypercholesterolemia and cardiovascular disease: efficacy and adverse events after 8,500 procedures.Current view: indications for extracorporeal lipid apheresis treatment.The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.Fatal myocardial infarction at 4.5 years in a case of homozygous familial hypercholesterolaemia.Characteristics of carotid atherosclerotic plaques of chronic lipid apheresis patients as assessed by in vivo high-resolution CMR--a comparative analysisLipoprotein (a): a Unique Independent Risk Factor for Coronary Artery Disease.The genetic basis of familial hypercholesterolemia: inheritance, linkage, and mutations.Cholesterol in pregnancy: a review of knowns and unknowns.Systematic Review of Low-Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia.PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016.Intolerance to statins: mechanisms and management.Treatment of dyslipidaemia in childhood.Mipomersen as a potential adjunctive therapy for hypercholesterolemia.Pharmacotherapy of dyslipidemias in the adult population.Emerging options in the treatment of dyslipidemias: a bright future?Lipid apheresis, indications, and principles.Defining the role of lipoprotein apheresis in the management of familial hypercholesterolemia.Low-density lipoprotein apheresis: principles and indications.LDL apheresis and inflammation--implications for atherosclerosis.
P2860
Q24623225-F90EC073-CF10-4721-BA41-5F585E8AA3A4Q26740292-BAC3A990-708D-4879-A2CE-5CB8BC3578EBQ26787050-DD2B352A-98A5-40EB-83F0-23387D8049A9Q26798119-8AE334FC-C0C1-4054-96F7-04B739EFC08AQ26828489-DA89DCF2-6A37-4DA8-9A29-FB0A3A21CC65Q30244116-818BDF7B-F945-4060-9A2E-93D189072FFBQ33165774-8BC18AA4-197D-4EEA-92EB-7C31C944879AQ33801207-CDA97854-E73B-4BE0-9BE8-F223A5B25350Q33803782-1409E109-FF7F-425B-B063-97880275E356Q33875391-43050FFF-214C-4487-8694-B531F9405F0DQ34122035-49498640-474C-48B8-BB68-BDD0D236562CQ34268963-7E942529-75E0-4B43-9946-BEECD069BA1EQ34284716-17162047-42B6-4F94-9FA9-61B169DC1D72Q34467839-D7918106-6A60-490C-87B0-8CD8CFF3A537Q34477657-6F8BE5F5-4BB3-4B1F-8F12-5868201AE379Q34541236-7F908AB7-7B59-4F48-A3E1-DECA9688C54AQ35043485-DA8DB66E-6C5F-438B-8E0D-9F122D59BE18Q35726039-5BFB86ED-FC8D-4142-9A35-CA752C5900EFQ35768586-4C2ADEB3-EC04-4AA7-935F-FC2AB43FE2DEQ35771729-37171C45-1110-41DE-8CEA-9320B74A43CEQ35839693-9DD8741A-F7E2-4AD3-A706-FD58FD6ABDF4Q36028557-7C114185-133E-4F2E-A622-021E7BAAD9D9Q36028650-22174AB6-2C8D-4336-A9E6-E3317241257EQ36069577-87567B5C-6A2F-4199-BC63-41C328EDFD81Q36433279-3664F792-455D-489E-B801-82DFA829B4C9Q36471825-9CA93422-C466-4D45-8799-8AD9EB10DF2CQ36515765-35B65C82-E418-48A1-AB10-F9F5D772B5D3Q36925157-98B471D5-0278-4AD8-BAF3-1D7419C7AC6CQ37185977-057D5459-93B5-4443-A4A5-829F5C910B5CQ37240649-7E0DDE4A-7BE6-4A59-B83F-475893CB617AQ37549374-7599F075-F1C0-4B48-B351-C1B17140955EQ37577161-F17FC6C5-DF56-42FB-9C03-4E9A5FC3AD82Q37704394-8371E7BC-8E19-446B-A995-79038E0E6136Q37779776-5A86873E-486C-44AC-8E6C-A79F34ED8971Q37801374-A6720642-662B-47BA-8103-99D76B3AC059Q37842462-0EB06F2A-31EC-4E03-B602-B8D16443B3A2Q37915431-5F745ECF-5AEB-4DF9-9FB1-669E78FBC4B2Q37965588-54631DDF-389E-4FAA-B45D-1BD010645FB1Q37978674-15CFACFF-C2FE-48C9-B324-D58CC38A9A12Q38016475-DAFEE148-9200-4683-85C0-35239C3D010F
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Recommendations for the use of LDL apheresis.
@ast
Recommendations for the use of LDL apheresis.
@en
Recommendations for the use of LDL apheresis.
@nl
type
label
Recommendations for the use of LDL apheresis.
@ast
Recommendations for the use of LDL apheresis.
@en
Recommendations for the use of LDL apheresis.
@nl
prefLabel
Recommendations for the use of LDL apheresis.
@ast
Recommendations for the use of LDL apheresis.
@en
Recommendations for the use of LDL apheresis.
@nl
P1433
P1476
Recommendations for the use of LDL apheresis.
@en
P2093
G R Thompson
HEART-UK LDL Apheresis Working Group
P304
P356
10.1016/J.ATHEROSCLEROSIS.2008.02.009
P577
2008-02-19T00:00:00Z